Medtronic
NYSE: MDT
$83.20 ▲ +1.19  (+1.45%)
At close: Jul 24, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap105.01 Bn
P/E21.73
P/S2.89
Div. Yield0.03
ROIC (Qtr)0.01
Total Debt (Qtr)27.96 Bn
Revenue Growth (1y) (Qtr)9.86
Add ratio to table…

About

Medtronic plc is a leading global healthcare technology company that develops manufactures and markets device based medical therapies and services. Founded in 1949 the company is headquartered in Galway Ireland and serves healthcare systems physicians clinicians and patients in more than 150 countries worldwide. Its mission drives the application of biomedical engineering to alleviate pain restore health and extend life. Medtronic pursues accelerated innovation by investing…

Read more ↓
Sector: Healthcare Industry: Medical Devices CIK: 0001613103

Investment Thesis

▲ Bull case
  • Medtronic is underestimating the long-term compounding effect of its strategic focus on high-growth adjacencies like Cardiac Ablation Solutions (CAS), Hugo robotics, and Altaviva, which together form a self-reinforcing ecosystem of innovation-driven growth that will outpace market expectations through 2028 and beyond. CAS is not merely growing at 78% organically in Q4 FY26 but is building a durable moat through its integrated EP ecosystem—Sphere-9, Prism-2 mapping, Sphere-360 catheter, and Affera platform—creating stickiness that locks in physician adoption and catheter pull-through, with installed base up 40% sequentially in the U.S. alone, signaling a multi-year runway for recurring revenue expansion. Simultaneously, Hugo’s surgical robotics platform is gaining traction not just in procedure volume (2x-3x market growth) but through its Touch Surgery digital ecosystem, now in over 1,400 ORs globally with 30% sequential growth, which enhances utilization, reduces friction in adoption, and drives pull-through on disposables and services—turning Hugo from a capital expense into a sticky, high-margin recurring revenue engine. Altaviva’s same-day activation, 15-year longevity, and full-body MRI compatibility are addressing a massive unmet need in urge urinary incontinence, with active implanters up 3x and patients treated up 2.5x sequentially, indicating that prior authorization bottlenecks are breaking and physician confidence is accelerating adoption beyond early adopters into mainstream urology and gynecology practices. These three platforms are not isolated bets but interconnected nodes in a broader strategy where robotics (Hugo), digital (Touch Surgery, Prism-2), and catheter-based therapies (CAS, Altaviva) create cross-selling opportunities and shared commercial infrastructure, reducing customer acquisition cost and increasing lifetime value—effects that are not yet priced into the stock because management frames them as incremental rather than transformative. The market is missing that Medtronic is transitioning from a device seller to an integrated therapy solutions provider, a shift that could sustain double-digit organic growth in these segments even as legacy businesses mature, with CAS alone on track to exceed $3 billion in annual revenue by FY28 if current adoption rates hold.
  • The market is overlooking the asymmetric upside potential from Medtronic’s targeted M&A and venture investments—particularly in ICE catheter technology via Beluga Medical and CardioACC, neurovascular via Scientia, and chronic pain via SPR Therapeutics—as these are not just financial bets but strategic platforms designed to extend Medtronic’s dominance in adjacent, high-growth markets where it already holds leadership positions. The CathWorks acquisition, which uses AI-driven FFRangio to disrupt the $1B wire-based FFR market growing at low double digits, presents a near-term catalyst: with positive 1-year ALL-RISE trial data validating its noninvasive approach, CathWorks is positioned to capture share rapidly in the cath lab, especially as hospitals seek to reduce procedure time and radiation exposure—potentially adding $200–$300M in incremental revenue by FY28 with gross margins above 70%, significantly boosting Medtronic’s Corporate and Growth Technology segment profitability. Similarly, the SPR Therapeutics acquisition for peripheral nerve stimulation (PNS) targets a market growing over 20% annually, where Medtronic’s neuromodulation expertise and commercial footprint can accelerate adoption far beyond organic growth, especially as reimbursement pathways for PNS mature and opioid-sparing alternatives gain traction. The Beluga Medical and CardioACC investments in next-gen ICE catheters are critical to fortifying the Affera platform’s EP ecosystem, enabling real-time tissue characterization during ablation—addressing a key limitation of current PFA tech and positioning Medtronic to dominate the next generation of hybrid ablation procedures. These are not speculative ventures; they are tuck-ins aligned with Medtronic’s capital allocation priorities, with recent M&A expected to contribute ~$150M to inorganic revenue in FY27 and accrete to organic growth thereafter through cross-selling and platform integration. The market treats these as noise, but they represent a systematic de-risking of innovation—leveraging Medtronic’s scale to validate and commercialize emerging tech faster than pure-play startups, with minimal dilution (only 2% assumed in guidance) and high probability of success given the company’s regulatory, reimbursement, and commercial execution advantages.
  • Medtronic’s guidance for FY27 organic revenue growth of 6.75%–7.25% is conspicuously conservative given the accelerating tailwinds from the extra selling week (+125 basis points to full-year growth), the lapping of tariff headwinds in H2 FY27, and the improving gross margin trajectory driven by CAS mix improvement and Diabetes separation—factors that together imply a meaningful upside to the midpoint of EPS guidance ($5.90–$6.00) that is not reflected in current consensus estimates. The company explicitly noted that excluding tariffs, gross margin is expected to be “very slightly up” in FY27, with better performance in the second half as the CAS mix shifts toward higher-margin catheters and Diabetes-related dilution lifts margins post-separation—yet the guidance assumes no benefit from the anticipated MiniMed spin-off, treating it as a full-year drag despite management’s stated intent to separate before year-end. This conservatism creates a clear path to EPS upside: if MiniMed separates in Q3 or Q4 FY27, the dilution drag lifts, the extra selling week benefit persists, and tariff impacts lap—potentially unlocking 100–150 basis points of operating margin expansion beyond the guided 60 basis point increase, which could drive EPS to $6.20–$6.50 even without acceleration in organic growth. Furthermore, the company’s free cash flow generation—$5.4B in FY26, strongest since 2022—provides ample flexibility to accelerate share repurchases or strategic tuck-ins if growth exceeds expectations, a lever not priced into the stock. The market is pricing Medtronic as a steady 5–6% grower, but the convergence of operational leverage, lapsing headwinds, and strategic separation creates a scenario where FY27 could deliver 8%+ organic growth and EPS well above guided ranges, particularly if CAS sustains its >2x market growth trajectory and Hugo/Altaviva continue their inflection points.
Read more
▼ Bear case
  • Medtronic’s Cardiac Ablation Solutions (CAS) growth, while impressive in headline numbers, is increasingly vulnerable to intensifying competition and pricing pressure that management has not adequately addressed, posing a significant risk to the sustainability of its >2x market growth trajectory and the premium valuation implied by its current guidance. Although CAS delivered 78% worldwide growth and gained 8 points of U.S. share in Q4 FY26, the underlying market grew ~20% in the quarter—meaning Medtronic is capturing share rapidly, but this pace is unlikely to persist as larger competitors like Boston Scientific and Abbott accelerate their PFA investments, and new entrants with deeper pockets enter the space. Management’s focus on expanding the EP ecosystem (Sphere-9, Prism-2, Affera, ICE catheter investments) assumes proprietary lock-in, but the reality is that mapping and catheter technologies are becoming commoditized, with physicians increasingly able to mix-and-match tools across platforms due to improving interoperability standards and hospital purchasing pressure to reduce vendor lock-in—undermining the assumed pull-through and recurring revenue benefits. Furthermore, the Affera platform’s reliance on pulsed field ablation (PFA) technology faces growing scrutiny over long-term safety data, particularly regarding esophageal injury and pulmonary vein stenosis, with no long-term RCTs beyond 3 years yet published; if safety concerns emerge, reimbursement could be restricted or physician adoption could stall, directly threatening the $2B annualized revenue run rate Medtronic cites as a foundation for FY27 growth. The company’s bullish narrative assumes CAS will continue to grow north of 2x the market rate indefinitely, but in reality, as the market saturates with early adopters and shifts to cost-conscious hospitals, growth will decelerate to market-matching or worse—especially if Medtronic’s premium pricing for Sphere-9 and Affera systems faces pushback in value-based purchasing environments, a risk highlighted by the flat performance in Structural Heart due to similar market dynamics.
  • The Hugo robotic surgery platform, despite positive early feedback and procedure volume growth of 2x–3x the market, remains a significant capital-intensive investment with unclear path to profitability, and its contribution to Medtronic’s overall margin and EPS is likely to be delayed and marginal due to intense competition from Intuitive Surgical’s da Vinci system and the high cost of hospital capital approvals in a tightening macro environment. While Medtronic highlights Touch Surgery’s 1,400+ global installations and 30% sequential growth as a differentiator, this digital ecosystem alone does not overcome the fundamental barrier that Hugo is a late entrant in a market dominated by a single player with >80% share, entrenched surgeon training networks, and proven clinical outcomes across dozens of procedures—advantages Hugo cannot replicate quickly, especially as it has only recently launched in urology and is still seeking clearance for General Surgery and Gynecologic indications. The company’s assumption that Hugo will drive pull-through on disposables and services is unproven; early adopters may use Hugo for index procedures but revert to legacy systems for routine cases due to workflow disruption, lack of haptic feedback, or insufficient cost-benefit justification—particularly as hospitals scrutinize ROI on capital equipment amid rising interest rates and constrained budgets. Furthermore, the R&D and SG&A investment required to sustain Hugo’s commercial launch, regulatory expansions, and surgeon training is substantial and ongoing, meaning that even if procedure volumes grow, the segment may remain a drag on consolidated operating margin for years, contradicting management’s implication that Hugo is already contributing meaningfully to profitability and that its growth will normalize rather than accelerate in FY27 guidance. The market may be overestimating Hugo’s ability to become a meaningful earnings contributor before FY29, and any delay in achieving scale or margin expansion would directly undermine the operating leverage thesis embedded in the FY27 guidance.
  • Medtronic’s reliance on Symplicity Ardian as a major growth driver for hypertension treatment is built on fragile reimbursement foundations and uncertain long-term durability, creating a material risk that the $100 million annualized run rate cited in Q4 FY26 will not scale meaningfully without sustained policy shifts and broader clinical adoption beyond early-adopter centers, a prospect that remains distant despite promising 3-year data. Although Symplicity demonstrated sustained systolic BP reductions of 13.3–18.1 mmHg at 3 years in over 2,000 patients and benefits from a broad label and growing prior authorization approvals, the therapy remains confined to a narrow subset of hypertensive patients—those with resistant hypertension who have failed multiple medications—representing only a fraction of the 18 million uncontrolled hypertension cases in the U.S. cited by management. Crucially, reimbursement remains inconsistent: while the National Coverage Determination (NCD) enabled Medicare coverage, many private payers still impose steep prior authorization hurdles or offer inadequate rates, and the company’s claim of “doubled average weekly procedure volumes since the NCD” is misleading without context—starting from a near-zero base, doubling still implies low absolute volume. Furthermore, the long-term durability of renal denervation’s BP effect beyond 3 years is unproven, and if durability wanes or safety signals emerge (e.g., renal artery stenosis), physician enthusiasm could fade quickly, especially as new pharmacologic therapies like SGLT2 inhibitors and finerenone continue to demonstrate robust cardiovascular outcomes in broader populations. Medtronic’s strategy assumes Symplicity will redefine the standard of care in hypertension, but in reality, it remains a niche procedure with limited addressable market, and without a breakthrough in reimbursement scalability or evidence of mortality benefit (not just BP reduction), its growth will plateau well below the levels implied by the company’s early-innings narrative, making the $100M run rate a ceiling rather than a floor for future expansion.
Read more

Debt Instrument Breakdown of Revenue (2018)

Debt Instrument Breakdown of Revenue (2018)

Peer Comparison

Companies in the Medical Devices
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 ABT Abbott Laboratories 201.40 Bn27.984.4634.05 Bn
2 SYK Stryker Corp 122.29 Bn36.604.8414.72 Bn
3 MDT Medtronic plc 105.01 Bn21.732.8927.96 Bn
4 BSX Boston Scientific Corp 64.81 Bn18.163.1411.03 Bn
5 EW Edwards Lifesciences Corp 55.28 Bn2,354.768.770.60 Bn
6 DXCM Dexcom Inc 29.06 Bn29.176.03-
7 PHG Koninklijke Philips Nv 29.02 Bn22.061.429.48 Bn
8 GEHC GE HealthCare Technologies Inc. 28.27 Bn14.301.3510.14 Bn